Skip to main content
placeholder image

Berberine alleviates olanzapine-induced adipogenesis via the AMPKα-SREBP pathway in 3T3-L1 cells

Journal Article


Download full-text (Open Access)

Abstract


  • The aim of this study was to investigate the mechanisms underlying the inhibitory effects of berberine (BBR) on olanzapine (OLZ)-induced adipogenesis in a well-replicated 3T3-L1 cell model. Oil-Red-O (ORO) staining showed that BBR significantly decreased OLZ-induced adipogenesis. Co-treatment with OLZ and BBR decreased the accumulation of triglyceride (TG) and total cholesterol (TC) by 55.58% ± 3.65% and 49.84% ± 8.31%, respectively, in 3T3-L1 adipocytes accompanied by reduced expression of Sterol regulatory element binding proteins 1 (SREBP1), fatty acid synthase (FAS), peroxisome proliferator activated receptor-¿ (PPAR¿), SREBP2, low-density lipoprotein receptor (LDLR), and hydroxymethylglutaryl-coenzyme A reductase (HMGR) genes compared with OLZ alone. Consistently, the co-treatment downregulated protein levels of SREBP1, SREBP2, and LDLR by 57.71% ± 9.42%, 73.05% ± 11.82%, and 59.46% ± 9.91%, respectively. In addition, co-treatment reversed the phosphorylation level of AMP-activated protein kinase-¿ (AMPK¿), which was reduced by OLZ, determined via the ratio of pAMPK¿:AMPK¿ (94.1%) compared with OLZ alone. The results showed that BBR may prevent lipid metabolism disorders caused by OLZ by reversing the degree of SREBP pathway upregulated and the phosphorylation of AMPK¿ downregulated. Collectively, these results indicated that BBR could be used as a potential adjuvant to prevent dyslipidemia and obesity caused by the use of second-generation antipsychotic medication.

Authors


  •   Li, Yan Jie (external author)
  •   Zhao, Xiaomin (external author)
  •   Feng, Xiyu (external author)
  •   Liu, Xuemei (external author)
  •   Deng, Chao
  •   Hu, Chang-Hua (external author)

Publication Date


  • 2016

Citation


  • Li, Y., Zhao, X., Feng, X., Liu, X., Deng, C. & Hu, C. (2016). Berberine alleviates olanzapine-induced adipogenesis via the AMPKα-SREBP pathway in 3T3-L1 cells. International Journal of Molecular Sciences, 17 (11), 1865-1-1865-12.

Scopus Eid


  • 2-s2.0-84994850786

Ro Full-text Url


  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=1960&context=ihmri

Ro Metadata Url


  • help http://ro.uow.edu.au/ihmri/935

Start Page


  • 1865-1

End Page


  • 1865-12

Volume


  • 17

Issue


  • 11

Abstract


  • The aim of this study was to investigate the mechanisms underlying the inhibitory effects of berberine (BBR) on olanzapine (OLZ)-induced adipogenesis in a well-replicated 3T3-L1 cell model. Oil-Red-O (ORO) staining showed that BBR significantly decreased OLZ-induced adipogenesis. Co-treatment with OLZ and BBR decreased the accumulation of triglyceride (TG) and total cholesterol (TC) by 55.58% ± 3.65% and 49.84% ± 8.31%, respectively, in 3T3-L1 adipocytes accompanied by reduced expression of Sterol regulatory element binding proteins 1 (SREBP1), fatty acid synthase (FAS), peroxisome proliferator activated receptor-¿ (PPAR¿), SREBP2, low-density lipoprotein receptor (LDLR), and hydroxymethylglutaryl-coenzyme A reductase (HMGR) genes compared with OLZ alone. Consistently, the co-treatment downregulated protein levels of SREBP1, SREBP2, and LDLR by 57.71% ± 9.42%, 73.05% ± 11.82%, and 59.46% ± 9.91%, respectively. In addition, co-treatment reversed the phosphorylation level of AMP-activated protein kinase-¿ (AMPK¿), which was reduced by OLZ, determined via the ratio of pAMPK¿:AMPK¿ (94.1%) compared with OLZ alone. The results showed that BBR may prevent lipid metabolism disorders caused by OLZ by reversing the degree of SREBP pathway upregulated and the phosphorylation of AMPK¿ downregulated. Collectively, these results indicated that BBR could be used as a potential adjuvant to prevent dyslipidemia and obesity caused by the use of second-generation antipsychotic medication.

Authors


  •   Li, Yan Jie (external author)
  •   Zhao, Xiaomin (external author)
  •   Feng, Xiyu (external author)
  •   Liu, Xuemei (external author)
  •   Deng, Chao
  •   Hu, Chang-Hua (external author)

Publication Date


  • 2016

Citation


  • Li, Y., Zhao, X., Feng, X., Liu, X., Deng, C. & Hu, C. (2016). Berberine alleviates olanzapine-induced adipogenesis via the AMPKα-SREBP pathway in 3T3-L1 cells. International Journal of Molecular Sciences, 17 (11), 1865-1-1865-12.

Scopus Eid


  • 2-s2.0-84994850786

Ro Full-text Url


  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=1960&context=ihmri

Ro Metadata Url


  • help http://ro.uow.edu.au/ihmri/935

Start Page


  • 1865-1

End Page


  • 1865-12

Volume


  • 17

Issue


  • 11